1
|
Tan SX, Aung TN, Claeson M, Acs B, Zhou C, Brown S, Lambie D, Baade PD, Pandeya N, Soyer HP, Smithers BM, Whiteman DC, Rimm DL, Khosrotehrani K. Automated scoring of tumor-infiltrating lymphocytes informs risk of death from thin melanoma: A nested case-case study. J Am Acad Dermatol 2024; 90:179-182. [PMID: 37730017 DOI: 10.1016/j.jaad.2023.09.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Revised: 06/14/2023] [Accepted: 09/02/2023] [Indexed: 09/22/2023]
Affiliation(s)
- Samuel X Tan
- Frazer Institute, University of Queensland, Brisbane, Australia
| | - Thazin N Aung
- Department of Pathology, Yale University School of Medicine, New Haven, Connecticut
| | - Magdalena Claeson
- Frazer Institute, University of Queensland, Brisbane, Australia; Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - Balazs Acs
- Department of Pathology, Yale University School of Medicine, New Haven, Connecticut; Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden; Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden
| | - Chenhao Zhou
- Frazer Institute, University of Queensland, Brisbane, Australia
| | - Susan Brown
- Frazer Institute, University of Queensland, Brisbane, Australia
| | - Duncan Lambie
- Pathology Queensland, Princess Alexandra Hospital, Brisbane, Australia
| | | | - Nirmala Pandeya
- Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Australia; School of Public Health, Faculty of Medicine, University of Queensland
| | - H Peter Soyer
- Frazer Institute, The University of Queensland, Dermatology Research Centre, Brisbane, Australia; Department of Dermatology, Princess Alexandra Hospital, Brisbane, Australia
| | - B Mark Smithers
- Queensland Melanoma Project, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
| | - David C Whiteman
- Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - David L Rimm
- Department of Pathology, Yale University School of Medicine, New Haven, Connecticut
| | - Kiarash Khosrotehrani
- Frazer Institute, University of Queensland, Brisbane, Australia; Department of Dermatology, Princess Alexandra Hospital, Brisbane, Australia.
| |
Collapse
|
2
|
Dorwal P, Lambie D, Dettrick A, Goh AFN, Kumar B, Manders P. A novel FET-ETS family fusion (FUS::FLI1) in a case of Ewing sarcoma. Pathol Int 2023; 73:563-565. [PMID: 37606217 DOI: 10.1111/pin.13373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2023] [Revised: 08/01/2023] [Accepted: 08/04/2023] [Indexed: 08/23/2023]
Affiliation(s)
- Pranav Dorwal
- Monash Health, Clayton, VIC, Australia
- Department of Medicine, Monash University, Clayton, VIC, Australia
| | - Duncan Lambie
- Pathology Queensland, Princess Alexandra Hospital, Woolloongabba, QLD, Australia
- Diamantina Institute, University of Queensland, St Lucia, QLD, Australia
| | - Andrew Dettrick
- Pathology Queensland, Sunshine Coast University Hospital, Birtinya, QLD, Australia
- Department of Medicine, The University of the Sunshine Coast, Sippy Downs, QLD, Australia
| | | | - Beena Kumar
- Monash Health, Clayton, VIC, Australia
- Department of Medicine, Monash University, Clayton, VIC, Australia
| | - Peter Manders
- Department of Medicine, The University of the Sunshine Coast, Sippy Downs, QLD, Australia
- Sunshine Coast University Hospital, Birtinya, QLD, Australia
| |
Collapse
|
3
|
Gupta R, Selinger CI, Ashford B, Chua MST, Clark JR, Damian DL, Jackett LA, James C, Johnson S, Ladwa R, Lambie D, McKenzie C, Tan ST, Scolyer RA. Implementing structured pathology reporting protocol for non-melanocytic skin cancers: practical considerations. Pathology 2023; 55:743-759. [PMID: 37573165 DOI: 10.1016/j.pathol.2023.07.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2023] [Revised: 07/22/2023] [Accepted: 07/26/2023] [Indexed: 08/14/2023]
Abstract
Non-melanocytic skin cancers (NMSCs) account for five times the incidence of all other cancers combined and cost US $6 billion annually. These are the most frequent specimens encountered in community pathology practice in many Western countries. Lack of standardised structured pathology reporting protocols (SPRPs) can result in omission of critical information or miscommunication leading to suboptimal patient management. The lack of standardised data has significant downstream public health implications, including insufficient data for reliable development of prognostic tools and health-economy planning. The Royal College of Pathologists of Australasia has developed an NMSC SPRP. A multidisciplinary expert committee including pathologists, surgeons, dermatologists, and radiation and medical oncologists from high volume cancer centres was convened. A systematic literature review was performed to identify evidence for including elements as mandatory standards or best practice guidelines. The SPRP and accompanying commentary of evidence, definitions and criteria was peer reviewed by external stakeholders. Finally, the protocol was revised following feedback and trialled in multiple centres prior to implementation. Some parameters utilised clinically for determining management and prognosis including tumour depth, lymphovascular invasion or distance to the margins lack high level evidence in NMSC. Dermatologists, surgeons, and radiation oncologists welcomed the SPRP. Pathologists indicated that the variety of NMSC specimens ranging from curettes to radical resections as well as significant differences in the biological behaviour of different tumours covered by the NMSC umbrella made use of a single protocol difficult. The feedback included that using a SPRP for low risk NMSC was neither clinically justified nor compensated adequately by the Australian Medicare Reimbursement Schedule. Following stakeholder feedback, the SPRP implementation was restricted to excision specimens of head and neck NMSC; and low-risk NMSC, such as superficial basal cell carcinoma, were excluded. Implementing NMSC SPRP fulfils an unmet clinical need. Unlike other cancers, NMSCs generate a range of specimen types and are reported in a wide range of pathology practices. Limiting use of SPRP to NMSC at higher risk of progression and providing formatted templates for easy incorporation into laboratory information systems were essential to successful deployment. In the future, further consideration should be given to implementing the SPRP to include all relevant specimens, including non-head and neck and low-risk NMSC specimens.
Collapse
Affiliation(s)
- Ruta Gupta
- Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, NSW Health Pathology, Sydney, NSW, Australia.
| | | | - Bruce Ashford
- Illawarra Health and Medical Research Institute, Wollongong, NSW, Australia; Department of Head and Neck Surgery, Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, NSW, Australia; Illawarra and Shoalhaven Local Health District, Wollongong, NSW, Australia; School of Medicine, University of Wollongong, Wollongong, NSW, Australia
| | - Margaret S T Chua
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Vic, Australia; The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Vic, Australia
| | - Jonathan R Clark
- Department of Head and Neck Surgery, Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, NSW, Australia; Royal Prince Alfred Institute of Academic Surgery, Sydney Local Health District, Sydney, NSW, Australia; Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
| | - Diona L Damian
- Discipline of Dermatology, Bosch Institute, University of Sydney, and Royal Prince Alfred Hospital Sydney, Sydney, NSW, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
| | - Louise A Jackett
- Department of Pathology, Austin Health, Melbourne, Vic, Australia
| | | | | | - Rahul Ladwa
- Department of Cancer Care Services, Princess Alexandra Hospital, Woolloongabba, Qld, Australia; Faculty of Medicine, University of Queensland, Herston, Qld, Australia
| | - Duncan Lambie
- Princess Alexandra Hospital, Pathology Queensland, Brisbane, Qld, Australia; Frazer Institute, University of Queensland, Brisbane, Qld, Australia
| | - Catriona McKenzie
- Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, NSW Health Pathology, Sydney, NSW, Australia
| | - Swee T Tan
- Gillies McIndoe Research Institute, Wellington, New Zealand; Wellington Regional Plastic, Maxillofacial and Burns Unit, Hutt Hospital, Wellington, New Zealand; Department of Surgery, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Vic, Australia
| | - Richard A Scolyer
- Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, NSW Health Pathology, Sydney, NSW, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia
| |
Collapse
|
4
|
Claeson M, Tan SX, Lambie D, Brown S, Walsh MD, Baade PD, Pandeya N, Whitehead KJ, Soyer HP, Smithers BM, Whiteman DC, Khosrotehrani K. The association between BRAF-V600E mutations and death from thin (≤1.00 mm) melanomas: A nested case-case study from Queensland, Australia. J Eur Acad Dermatol Venereol 2023; 37:e1168-e1172. [PMID: 37147869 DOI: 10.1111/jdv.19173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2022] [Accepted: 04/26/2023] [Indexed: 05/07/2023]
Affiliation(s)
- M Claeson
- Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
- Dermatology Research Centre, Experimental Dermatology Group, University of Queensland Diamantina Institute, Brisbane, Queensland, Australia
- Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - S X Tan
- Dermatology Research Centre, Experimental Dermatology Group, University of Queensland Diamantina Institute, Brisbane, Queensland, Australia
| | - D Lambie
- Anatomical Pathology, Princess Alexandra Hospital, Pathology Queensland, Brisbane, Queensland, Australia
- University of Queensland Diamantina Institute, Brisbane, Queensland, Australia
| | - S Brown
- Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
- Dermatology Research Centre, Experimental Dermatology Group, University of Queensland Diamantina Institute, Brisbane, Queensland, Australia
| | - M D Walsh
- Histopathology Department, Sullivan Nicolaides Pathology, Brisbane, Queensland, Australia
| | - P D Baade
- Cancer Council Queensland, Queensland, Australia
- Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland, Australia
- Centre for Data Science, Queensland University of Technology, Brisbane, Queensland, Australia
| | - N Pandeya
- Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - K J Whitehead
- Histopathology Department, Sullivan Nicolaides Pathology, Brisbane, Queensland, Australia
| | - H P Soyer
- Dermatology Research Centre, Experimental Dermatology Group, University of Queensland Diamantina Institute, Brisbane, Queensland, Australia
- Department of Dermatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia
| | - B M Smithers
- Queensland Melanoma Project, University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland, Australia
| | - D C Whiteman
- Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - K Khosrotehrani
- Dermatology Research Centre, Experimental Dermatology Group, University of Queensland Diamantina Institute, Brisbane, Queensland, Australia
- Department of Dermatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia
| |
Collapse
|
5
|
Chow KVC, O’Leary C, Paxton-Hall F, Lambie D, O’Byrne K. Pembrolizumab-induced toxic epidermal necrolysis: case report. Oxf Med Case Reports 2022; 2022:omac025. [PMID: 35317001 PMCID: PMC8931819 DOI: 10.1093/omcr/omac025] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2022] [Revised: 01/12/2022] [Accepted: 01/17/2022] [Indexed: 12/28/2022] Open
Abstract
A 63-year-old man with metastatic lung adenocarcinoma presented with biopsy confirmed toxic epidermal necrolysis (TEN). Symptoms commenced following 3 cycles of carboplatin, pemetrexed and pembrolizumab, with the first cycle given ~9.5 weeks prior to presentation. The patient was managed with immunosuppressive therapy including high dose methylprednisolone, cyclosporine, intravenous immunoglobulin, antibiotics and optimal skin care, and achieved excellent recovery of the skin lesions with minimal sequelae. This rare occurrence of pembrolizumab-induced TEN has only been reported previously in a few cases with limited evidence on management. Given the increasing use of immune checkpoint inhibitors and the long half-life of these agents, our case highlights the importance of recognizing this complication and of a multidisciplinary approach to management.
Collapse
Affiliation(s)
- Kar Ven Cavan Chow
- Medical Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
| | - Connor O’Leary
- Medical Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
- Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia
| | - Fiona Paxton-Hall
- Medical Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
| | - Duncan Lambie
- Anatomical Pathology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
| | - Kenneth O’Byrne
- Medical Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
- Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia
| |
Collapse
|
6
|
Muse ME, Bergman DT, Salas LA, Tom LN, Tan JM, Laino A, Lambie D, Sturm RA, Schaider H, Soyer HP, Christensen BC, Stark MS. Genome-scale DNA methylation analysis identifies repeat element alterations that modulate the genomic stability of melanocytic nevi. J Invest Dermatol 2021; 142:1893-1902.e7. [PMID: 34871578 DOI: 10.1016/j.jid.2021.11.025] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Revised: 11/16/2021] [Accepted: 11/18/2021] [Indexed: 12/31/2022]
Abstract
Acquired melanocytic nevi grow and persist in a stable form into adulthood. Using genome-wide methylation profiling, we evaluated 32 histopathologically and dermoscopically characterized nevi, to identify key epigenetic regulatory mechanisms involved in nevogenesis. Benign (69% globular and 31% non-specific dermoscopic pattern) and dysplastic (95% reticular/nonspecific dermoscopic pattern) nevi were dissimilar with only two shared differentially methylated (DM) loci. Benign nevi demonstrated an increase in both genome-scale methylation and methylation of Alu/LINE-1 retrotransposable elements, a marker of genomic stability, as well as global methylation. In contrast, dysplastic nevi showed evidence for genomic instability via hypomethylation of Alu/LINE-1 (Alu; P=0.00019 and LINE-1; P=0.000035). Using dermoscopic classifications, reticular/non-specific patterned nevi had 59,572 CpG DM loci (Q < 0.05), whereas globular nevi had no significant DM loci. In reticular/non-specific patterned nevi, the tumor suppressor PTEN had the greatest proportion of hypermethylated CpG loci in its promoter region compared to all other assayed gene promoters. The relative activity of reticular/non-specific nevi was evidenced by 50,720 hypomethylated loci being enriched for accessible chromatin, and 8,852 hypermethylated loci strongly enriched, for example, marks of active gene promoters, which suggests that gain of DNA methylation observed in these nevus types plays a role in gene regulation.
Collapse
Affiliation(s)
- Meghan E Muse
- Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA
| | - Drew T Bergman
- Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA
| | - Lucas A Salas
- Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA
| | - Lisa N Tom
- The University of Queensland Diamantina Institute, The University of Queensland, Dermatology Research Centre, Brisbane, Australia
| | - Jean-Marie Tan
- The University of Queensland Diamantina Institute, The University of Queensland, Dermatology Research Centre, Brisbane, Australia
| | - Antonia Laino
- The University of Queensland Diamantina Institute, The University of Queensland, Dermatology Research Centre, Brisbane, Australia
| | - Duncan Lambie
- IQ Pathology, Brisbane, Australia; Pathology Queensland, Princess Alexandra Hospital, Brisbane, Australia
| | - Richard A Sturm
- The University of Queensland Diamantina Institute, The University of Queensland, Dermatology Research Centre, Brisbane, Australia
| | - Helmut Schaider
- The University of Queensland Diamantina Institute, The University of Queensland, Dermatology Research Centre, Brisbane, Australia; Department of Dermatology, Sunshine Coast Hospital and Health Service, Birtinya, Australia
| | - H Peter Soyer
- The University of Queensland Diamantina Institute, The University of Queensland, Dermatology Research Centre, Brisbane, Australia; Department of Dermatology, Princess Alexandra Hospital, Brisbane, Australia
| | - Brock C Christensen
- Department of Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA; Department of Molecular & Systems Biology, Dartmouth Geisel School of Medicine, Hanover, New Hampshire, USA; Department of Community & Family Medicine, Dartmouth Geisel School of Medicine, Hanover, New Hampshire, USA
| | - Mitchell S Stark
- The University of Queensland Diamantina Institute, The University of Queensland, Dermatology Research Centre, Brisbane, Australia.
| |
Collapse
|
7
|
Scolyer RA, Atkinson V, Gyorki DE, Lambie D, O'Toole S, Saw RP, Amanuel B, Angel CM, Button-Sloan AE, Carlino MS, Ch'ng S, Colebatch AJ, Daneshvar D, Pires da Silva I, Dawson T, Ferguson PM, Foster-Smith E, Fox SB, Gill AJ, Gupta R, Henderson MA, Hong AM, Howle JR, Jackett LA, James C, Lee CS, Lochhead A, Loh D, McArthur GA, McLean CA, Menzies AM, Nieweg OE, O'Brien BH, Pennington TE, Potter AJ, Prakash S, Rawson RV, Read RL, Rtshiladze MA, Shannon KF, Smithers BM, Spillane AJ, Stretch JR, Thompson JF, Tucker P, Varey AH, Vilain RE, Wood BA, Long GV. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology 2021; 54:6-19. [DOI: 10.1016/j.pathol.2021.11.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Accepted: 11/21/2021] [Indexed: 01/19/2023]
|
8
|
Tian K, Johnstone K, Lambie D, Frankel A. Low-grade fibromyxoid sarcoma with high-grade features, a rare finding. ANZ J Surg 2021; 92:1519-1521. [PMID: 34708925 DOI: 10.1111/ans.17308] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Accepted: 10/10/2021] [Indexed: 11/27/2022]
Affiliation(s)
- Kevin Tian
- Department of Surgery, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.,Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia
| | - Kate Johnstone
- Department of Surgery, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.,Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia
| | - Duncan Lambie
- Department of Surgery, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.,Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia
| | - Adam Frankel
- Department of Surgery, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.,Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia
| |
Collapse
|
9
|
Mortimore AM, Barsoum R, Lambie D, McMeniman E. A case of omalizumab as a successful treatment for telangiectasia macularis eruptiva perstans. Australas J Dermatol 2021; 63:102-104. [PMID: 34314029 DOI: 10.1111/ajd.13674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Accepted: 07/05/2021] [Indexed: 11/26/2022]
Abstract
Treatment for telangiectasia macularis eruptiva perstans (TMEP) is often challenging due to lack of an established first-line therapy and as such is primarily focused on symptomatic relief. Omalizumab shows promise as a potential therapy for mast cell disorders; however, its efficacy in TMEP is yet to be established. This case describes a 72-year-old woman with chronic refractory TMEP achieving symptomatic remission within 4 months of commencing omalizumab therapy.
Collapse
Affiliation(s)
| | - Ramez Barsoum
- Department of Dermatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.,Queensland Institute of Dermatology, Brisbane, Queensland, Australia
| | - Duncan Lambie
- Department of Pathology, Princess Alexandra Hospital, Brisbane, Queensland, Australia
| | - Erin McMeniman
- Department of Dermatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.,Dermatology Research Centre, The University of Queensland Diamantina Institute, Brisbane, Queensland, Australia
| |
Collapse
|
10
|
Laurens JR, Frankel A, Lambie D. Heterotopic ossification within the gallbladder - First reported Australian case. Int J Surg Case Rep 2021; 81:105787. [PMID: 33756168 PMCID: PMC8020415 DOI: 10.1016/j.ijscr.2021.105787] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2021] [Accepted: 03/14/2021] [Indexed: 11/29/2022] Open
Abstract
INTRODUCTION We report the rare and unusual case of heterotopic ossification within the gallbladder secondary to chronic calculi debris. PRESENTATION OF CASE A 35-year-old female underwent routine laparoscopic cholecystectomy for recurrent intermittent right upper quadrant pain which had persisted for three months and was worse post prandial with associated nausea. Abdominal ultrasound prior to surgery was reported by a consultant radiologist as demonstrating a thin-walled gallbladder and cholelithiasis, without features of cholecystitis. At four-week review, she had recovered well with no concerns. The histopathology report revealed fibromuscular hyperplasia and patchy chronic inflammation. Rokitansky-Aschoff sinuses were present and cholesterosis was noted. Additionally, there was a focus of eroded mucosa showing adherent microlithiasis with an incidental focus of heterotopic ossification within the mucosa, there was no evidence of dysplasia or malignancy. DISCUSSION Gallbladder heterotopic ossification is exceedingly rare, with few cases reported. To our knowledge this is the first reported case in Australia. CONCLUSION In conclusion, we report the rare and unusual finding of heterotopic ossification of the gallbladder, and suspect that inflammation secondary to calculous debris initiated the ossification. Current technical limitations preclude diagnosis prior to surgery. Appropriate follow-up is unclear, but we feel a single report associated the finding with adenocarcinoma was sufficient to warrant follow-up.
Collapse
Affiliation(s)
- Jason Russell Laurens
- Department of Surgical Specialties, Princess Alexandra Hospital, Woolloongabba, QLD, 4102, Australia.
| | - Adam Frankel
- FRACS, University of Queensland, Princess Alexandra Hospital, Woolloongabba, QLD, 4102, Australia
| | - Duncan Lambie
- FRCPA, Diamantina Institute, University of Queensland and Pathology Queensland, Princess Alexandra Hospital, Woolloongabba, QLD, 4102, Australia
| |
Collapse
|
11
|
Chitsazan A, Lambie D, Ferguson B, Handoko HY, Gabrielli B, Walker GJ, Boyle GM. Unexpected High Levels of BRN2/POU3F2 Expression in Human Dermal Melanocytic Nevi. J Invest Dermatol 2019; 140:1299-1302.e4. [PMID: 31881210 DOI: 10.1016/j.jid.2019.12.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2019] [Revised: 11/27/2019] [Accepted: 12/07/2019] [Indexed: 01/13/2023]
Affiliation(s)
- Arash Chitsazan
- QIMR Berghofer Medical Research Institute, Herston, Australia
| | - Duncan Lambie
- IQ Pathology, West End, Brisbane, Australia and The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia
| | - Blake Ferguson
- QIMR Berghofer Medical Research Institute, Herston, Australia
| | | | - Brian Gabrielli
- Mater Medical Research Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia
| | - Graeme J Walker
- QIMR Berghofer Medical Research Institute, Herston, Australia; Experimental Dermatology, The University of Queensland Diamantina Institute, Translational Research Institute, Woolloongabba, Australia.
| | - Glen M Boyle
- QIMR Berghofer Medical Research Institute, Herston, Australia
| |
Collapse
|
12
|
Trada Y, Law P, Bernard A, Foote M, Barbour A, Lambie D, Smithers M, Burmeister B, Pinkham M. FDG-PET Response Assessment in Patients with Locally Advanced Nodal Melanoma Undergoing High-Dose Neo-Adjuvant or Definitive Radiotherapy. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.2489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
13
|
Yamada M, Annells P, Lambie D, Belt P, Prow T. 112 Skin micro-sampling device, MicrobiopsyTM is more sensitive to detect known melanoma and non-melanoma skin cancer biomarkers on volunteers. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
14
|
Joseph SR, Gaffney D, Barry R, Hu L, Banushi B, Wells JW, Lambie D, Strutton G, Porceddu SV, Burmeister B, Leggatt GR, Schaider H, Dolcetti R, Frazer IH, Saunders NA, Foote M, Soyer HP, Simpson F. An Ex Vivo Human Tumor Assay Shows Distinct Patterns of EGFR Trafficking in Squamous Cell Carcinoma Correlating to Therapeutic Outcomes. J Invest Dermatol 2019; 139:213-223. [DOI: 10.1016/j.jid.2018.06.190] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2018] [Revised: 05/31/2018] [Accepted: 06/10/2018] [Indexed: 01/26/2023]
|
15
|
Sobarun P, Hoang VLT, Yamada M, Lambie D, Soyer HP, Prow TW. Microbiopsy Biomarker Profiling in a Superficial Melanoma Resembling a Pigmented Basal Cell Carcinoma. JAMA Dermatol 2018; 153:334-336. [PMID: 28196220 DOI: 10.1001/jamadermatol.2016.5537] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Affiliation(s)
- Priyamvada Sobarun
- Dermatology Research Centre, The University of Queensland, Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia
| | - Van L T Hoang
- Dermatology Research Centre, The University of Queensland, Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia
| | - Miko Yamada
- Dermatology Research Centre, The University of Queensland, Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia
| | - Duncan Lambie
- IQ Pathology, West End, Brisbane, Queensland, Australia
| | - H Peter Soyer
- Dermatology Research Centre, The University of Queensland, Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia3Department of Dermatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia
| | - Tarl W Prow
- Dermatology Research Centre, The University of Queensland, Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia
| |
Collapse
|
16
|
Stark MS, Tan JM, Tom L, Jagirdar K, Lambie D, Schaider H, Soyer HP, Sturm RA. Abstract 5376: Whole-exome sequencing of acquired nevi identifies novel mechanisms for development and maintenance of benign neoplasms. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-5376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Acquired melanocytic nevi (AMN) are often mimicking melanoma and ~30% of all melanomas arise within a pre-existing nevus. However, the melanoma transformation rate of each nevus is rare despite the detection of oncogenic mutations BRAF or NRAS mutations in 100% of nevi.Objective: To identify the underlying genetic mechanisms for nevus development.Methods: Nevi, adjacent normal skin, and saliva were sampled from a cross-sectional study. All nevi were clinically, dermoscopically, and histopathologically documented. Using whole-exome sequencing (WES) we assessed the somatic mutational landscape, mutation signatures and copy-number aberrations (CNA) in 30 acquired melanocytic nevi and matching normal skin.Results: In addition to identifying somatic mutations, we confirm the presence of mutational signatures relating to age and ultra-violet radiation (UVR) which mirrors those observed in melanomas of the skin. In matching normal skin of all nevi, we rarely observed the presence of a UVR mutation signature (10% vs. 97% in nevi) despite being exposed to the same amount of UVR as the associated naevus. Instead, we have identified the predominance of defective DNA repair mutation signatures (93%) which we postulate creates the environment for melanocyte transformation sufficient for nevi and perhaps de novo melanoma growth. In copy number aberration (CNA) analysis, in nevi with copy number loss of tumour suppressor genes (TSG), these were balanced by loss of potent oncogenes. Moreover, reticular and non-specific patterned nevi revealed an increased (p<0.0001) number of CNA as compared with globular patterned nevi. Conclusion: The mutation signature data generated in this study confirms that UVR and defective DNA repair mechanism strongly contributes to nevogenesis. The observed copy number changes reflect at a genomic level, the dermoscopic differences of AMN. Lastly, we propose that the balanced loss of TSGs and oncogenes is a protective mechanism of AMN.
Citation Format: Mitchell S. Stark, Jean-Marie Tan, Lisa Tom, Kasturee Jagirdar, Duncan Lambie, Helmut Schaider, H. Peter Soyer, Richard A. Sturm. Whole-exome sequencing of acquired nevi identifies novel mechanisms for development and maintenance of benign neoplasms [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5376.
Collapse
Affiliation(s)
| | - Jean-Marie Tan
- 1Univ. of Queensland Diamantina Institute, Brisbane, Australia
| | - Lisa Tom
- 1Univ. of Queensland Diamantina Institute, Brisbane, Australia
| | | | | | - Helmut Schaider
- 1Univ. of Queensland Diamantina Institute, Brisbane, Australia
| | - H. Peter Soyer
- 1Univ. of Queensland Diamantina Institute, Brisbane, Australia
| | | |
Collapse
|
17
|
Stark MS, Tan JM, Tom L, Jagirdar K, Lambie D, Schaider H, Soyer HP, Sturm RA. Whole-Exome Sequencing of Acquired Nevi Identifies Mechanisms for Development and Maintenance of Benign Neoplasms. J Invest Dermatol 2018; 138:1636-1644. [PMID: 29476775 DOI: 10.1016/j.jid.2018.02.012] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2018] [Revised: 02/06/2018] [Accepted: 02/13/2018] [Indexed: 01/08/2023]
Abstract
The melanoma transformation rate of an individual nevus is very low despite the detection of oncogenic BRAF or NRAS mutations in 100% of nevi. Acquired melanocytic nevi do, however, mimic melanoma, and approximately 30% of all melanomas arise within pre-existing nevi. Using whole-exome sequencing of 30 matched nevi, adjacent normal skin, and saliva we sought to identify the underlying genetic mechanisms for nevus development. All nevi were clinically, dermoscopically, and histopathologically documented. In addition to identifying somatic mutations, we found mutational signatures relating to UVR mirroring those found in cutaneous melanoma. In nevi we frequently observed the presence of the UVR mutation signature compared with adjacent normal skin (97% vs. 10%, respectively). Copy number aberration analysis showed that for nevi with copy number loss of tumor suppressor genes, this loss was balanced by loss of potent oncogenes. Moreover, reticular and nonspecific patterned nevi showed an increased (P < 0.0001) number of copy number aberrations compared with globular nevi. The mutation signature data generated in this study confirms that UVR strongly contributes to nevogenesis. Copy number changes reflect at a genomic level the dermoscopic differences of acquired melanocytic nevi. Finally, we propose that the balanced loss of tumor suppressor genes and oncogenes is a protective mechanism of acquired melanocytic nevi.
Collapse
Affiliation(s)
- Mitchell S Stark
- Dermatology Research Centre, The University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia.
| | - Jean-Marie Tan
- Dermatology Research Centre, The University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia
| | - Lisa Tom
- Dermatology Research Centre, The University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia
| | - Kasturee Jagirdar
- Dermatology Research Centre, The University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia
| | | | - Helmut Schaider
- Dermatology Research Centre, The University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia; Department of Dermatology, Princess Alexandra Hospital, Brisbane, Australia
| | - H Peter Soyer
- Dermatology Research Centre, The University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia; Department of Dermatology, Princess Alexandra Hospital, Brisbane, Australia
| | - Richard A Sturm
- Dermatology Research Centre, The University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia
| |
Collapse
|
18
|
Tan J, Tom L, Jagirdar K, Lambie D, Schaider H, Sturm R, Soyer H, Stark M. 通过电子皮镜观察到在后天性痣亚型中常见 BRAF 和 NRAS 突变,表现出组成型 MAPK 通路活化. Br J Dermatol 2018. [DOI: 10.1111/bjd.16210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
19
|
Tan J, Tom L, Jagirdar K, Lambie D, Schaider H, Sturm R, Soyer H, Stark M. The
BRAF
and
NRAS
mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive mitogen‐activated protein kinase pathway activation. Br J Dermatol 2018. [DOI: 10.1111/bjd.16205] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
20
|
Tan JM, Tom LN, Jagirdar K, Lambie D, Schaider H, Sturm RA, Soyer HP, Stark MS. The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive mitogen-activated protein kinase pathway activation. Br J Dermatol 2017; 178:191-197. [PMID: 28714107 DOI: 10.1111/bjd.15809] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/11/2017] [Indexed: 01/23/2023]
Abstract
BACKGROUND Acquired naevi can have unique dermoscopic patterns that correspond to distinct microanatomical growth patterns. Previous studies on acquired naevi stratified according to dermoscopic pattern focused on the frequency of somatic BRAF mutations, whereas NRAS mutations remained to be elucidated. OBJECTIVES To investigate the BRAF and NRAS mutation prevalence and activation of the mitogen-activated protein kinase (MAPK) pathway in distinct dermoscopic subtypes of acquired naevi. METHODS Common mutations present in BRAF and NRAS were assessed in 40 globular, reticular and peripheral rim of globules (PG) subtypes of acquired naevi from 27 participants (19 male, 8 female; mean age 46·7 years) selected from 1261 eligible volunteers. Mutations were determined using the highly sensitive and quantitative QX200 droplet digital™ polymerase chain reaction (ddPCR) system. RESULTS The BRAF V600E (c.1799T>A or c.1799_1800delTGinsA) and BRAF V600K mutations were detected in 85% (n = 34/40) of naevi. All BRAF wild-type naevi (15%; n = 6/40) harboured an NRAS codon 12/13 or 61 mutation. BRAF mutations were present in 92% (n = 12/13) of globular and 100% (n = 12/12) of PG naevi, whereas reticular naevi were 67% (n = 10/15) BRAF- and 33% (n = 5/15) NRAS-mutant (P = 0·037). CONCLUSIONS We discovered that 100% of the assessed acquired naevi had either a BRAF or NRAS mutation. Using sensitive techniques capable of single-cell mutation detection, it is likely that all acquired naevi will be mutated for BRAF or NRAS. Because both of these mutations are prevalent in distinct dermoscopic naevus subsets, our study supports the role of the MAPK pathway in the development of benign melanocytic proliferations, indicating that additional genomic events besides somatic mutations in BRAF or NRAS are required for melanoma development.
Collapse
Affiliation(s)
- J M Tan
- Dermatology Research Centre, The University of Queensland, UQ Diamantina Institute, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, Brisbane, QLD, 4102, Australia
| | - L N Tom
- Dermatology Research Centre, The University of Queensland, UQ Diamantina Institute, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, Brisbane, QLD, 4102, Australia
| | - K Jagirdar
- Dermatology Research Centre, The University of Queensland, UQ Diamantina Institute, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, Brisbane, QLD, 4102, Australia
| | - D Lambie
- IQ Pathology, Brisbane, QLD, Australia
| | - H Schaider
- Dermatology Research Centre, The University of Queensland, UQ Diamantina Institute, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, Brisbane, QLD, 4102, Australia
| | - R A Sturm
- Dermatology Research Centre, The University of Queensland, UQ Diamantina Institute, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, Brisbane, QLD, 4102, Australia
| | - H P Soyer
- Dermatology Research Centre, The University of Queensland, UQ Diamantina Institute, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, Brisbane, QLD, 4102, Australia
| | - M S Stark
- Dermatology Research Centre, The University of Queensland, UQ Diamantina Institute, Level 5, Translational Research Institute, 37 Kent Street, Woolloongabba, Brisbane, QLD, 4102, Australia
| |
Collapse
|
21
|
Thomas S, Laino A, Sturm R, Nufer K, Lambie D, Shepherd B, Atkinson V, Adams L, Soyer HP, Schaider H. Focal regression of a primary melanoma, fading lentigines and poliosis in metastatic melanoma treated with anti-PD-1. J Eur Acad Dermatol Venereol 2017; 32:e176-e177. [PMID: 29114959 DOI: 10.1111/jdv.14678] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- S Thomas
- Dermatology Research Centre, The University of Queensland Diamantina Institute, Translational Research Institute, The University of Queensland, Brisbane, QLD, Australia.,Department of Dermatology, Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - A Laino
- Dermatology Research Centre, The University of Queensland Diamantina Institute, Translational Research Institute, The University of Queensland, Brisbane, QLD, Australia.,Department of Dermatology, Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - R Sturm
- Dermatology Research Centre, The University of Queensland Diamantina Institute, Translational Research Institute, The University of Queensland, Brisbane, QLD, Australia
| | - K Nufer
- Dermatology Research Centre, The University of Queensland Diamantina Institute, Translational Research Institute, The University of Queensland, Brisbane, QLD, Australia
| | - D Lambie
- Department of Dermatology, Princess Alexandra Hospital, Brisbane, QLD, Australia.,IQ Pathology, Brisbane, QLD, Australia
| | - B Shepherd
- Department of Dermatology, Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - V Atkinson
- Department of Medical Oncology, Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - L Adams
- Dermatology Research Centre, The University of Queensland Diamantina Institute, Translational Research Institute, The University of Queensland, Brisbane, QLD, Australia
| | - H P Soyer
- Dermatology Research Centre, The University of Queensland Diamantina Institute, Translational Research Institute, The University of Queensland, Brisbane, QLD, Australia.,Department of Dermatology, Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - H Schaider
- Dermatology Research Centre, The University of Queensland Diamantina Institute, Translational Research Institute, The University of Queensland, Brisbane, QLD, Australia
| |
Collapse
|
22
|
Hoang VLT, Tom LN, Quek XC, Tan JM, Payne EJ, Lin LL, Sinnya S, Raphael AP, Lambie D, Frazer IH, Dinger ME, Soyer HP, Prow TW. RNA-seq reveals more consistent reference genes for gene expression studies in human non-melanoma skin cancers. PeerJ 2017; 5:e3631. [PMID: 28852586 PMCID: PMC5572537 DOI: 10.7717/peerj.3631] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2016] [Accepted: 07/11/2017] [Indexed: 11/20/2022] Open
Abstract
Identification of appropriate reference genes (RGs) is critical to accurate data interpretation in quantitative real-time PCR (qPCR) experiments. In this study, we have utilised next generation RNA sequencing (RNA-seq) to analyse the transcriptome of a panel of non-melanoma skin cancer lesions, identifying genes that are consistently expressed across all samples. Genes encoding ribosomal proteins were amongst the most stable in this dataset. Validation of this RNA-seq data was examined using qPCR to confirm the suitability of a set of highly stable genes for use as qPCR RGs. These genes will provide a valuable resource for the normalisation of qPCR data for the analysis of non-melanoma skin cancer.
Collapse
Affiliation(s)
- Van L T Hoang
- Dermatology Research Centre, Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, The University of Queensland, Brisbane, Queensland, Australia
| | - Lisa N Tom
- Dermatology Research Centre, Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, The University of Queensland, Brisbane, Queensland, Australia
| | - Xiu-Cheng Quek
- Garvan Institute of Medical Research, Sydney, New South Wales, Australia.,St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia
| | - Jean-Marie Tan
- Dermatology Research Centre, Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, The University of Queensland, Brisbane, Queensland, Australia
| | - Elizabeth J Payne
- Dermatology Research Centre, Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, The University of Queensland, Brisbane, Queensland, Australia
| | - Lynlee L Lin
- Dermatology Research Centre, Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, The University of Queensland, Brisbane, Queensland, Australia
| | - Sudipta Sinnya
- Dermatology Research Centre, Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, The University of Queensland, Brisbane, Queensland, Australia
| | - Anthony P Raphael
- Dermatology Research Centre, Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, The University of Queensland, Brisbane, Queensland, Australia.,Wellman Center for Photomedicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA
| | - Duncan Lambie
- Department of Anatomical Pathology, Princess Alexandra Hospital, Brisbane, Queensland, Australia
| | - Ian H Frazer
- Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, The University of Queensland, Brisbane, Queensland, Australia
| | - Marcel E Dinger
- Garvan Institute of Medical Research, Sydney, New South Wales, Australia.,St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia
| | - H Peter Soyer
- Dermatology Research Centre, Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, The University of Queensland, Brisbane, Queensland, Australia
| | - Tarl W Prow
- Dermatology Research Centre, Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, The University of Queensland, Brisbane, Queensland, Australia.,Biomaterials Engineering and Nanomedicine Strand, Future Industries Institute, University of South Australia, Mawson Lakes, Australia
| |
Collapse
|
23
|
Lee WJ, Škalamera D, Dahmer-Heath M, Shakhbazov K, Ranall MV, Fox C, Lambie D, Stevenson AJ, Yaswen P, Gonda TJ, Gabrielli B. Genome-Wide Overexpression Screen Identifies Genes Able to Bypass p16-Mediated Senescence in Melanoma. SLAS Discov 2016; 22:298-308. [PMID: 27872202 DOI: 10.1177/1087057116679592] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Malignant melanomas often arise from nevi, which result from initial oncogene-induced hyperproliferation of melanocytes that are maintained in a CDKN2A/p16-mediated senescent state. Thus, genes that can bypass this senescence barrier are likely to contribute to melanoma development. We have performed a gain-of-function screen of 17,030 lentivirally expressed human open reading frames (ORFs) in a melanoma cell line containing an inducible p16 construct to identify such genes. Genes known to bypass p16-induced senescence arrest, including the human papilloma virus 18 E7 gene ( HPV18E7), and genes such as the p16-binding CDK6 with expected functions, as well as panel of novel genes, were identified, including high-mobility group box (HMGB) proteins. A number of these were further validated in two other models of p16-induced senescence. Tissue immunohistochemistry demonstrated higher levels of CDK6 in primary melanomas compared with normal skin and nevi. Reduction of CDK6 levels drove melanoma cells expressing functional p16 into senescence, demonstrating its contribution to bypass senescence.
Collapse
Affiliation(s)
- Won Jae Lee
- 1 The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia
| | - Dubravka Škalamera
- 1 The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia.,Mater Research Institute, The University of Queensland, Translational Research Institute, Brisbane, Queensland, Australia
| | - Mareike Dahmer-Heath
- 1 The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia.,Mater Research Institute, The University of Queensland, Translational Research Institute, Brisbane, Queensland, Australia
| | - Konstanin Shakhbazov
- 1 The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia.,Queensland Brain Institute, The University of Queensland, Brisbane, Queensland, Australia
| | - Max V Ranall
- 1 The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia
| | - Carly Fox
- 1 The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia
| | - Duncan Lambie
- 1 The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia
| | - Alexander J Stevenson
- 1 The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia.,Mater Research Institute, The University of Queensland, Translational Research Institute, Brisbane, Queensland, Australia
| | - Paul Yaswen
- 2 Environmental Genomics and Systems Biology Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
| | - Thomas J Gonda
- 3 School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia
| | - Brian Gabrielli
- 1 The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Queensland, Australia.,Mater Research Institute, The University of Queensland, Translational Research Institute, Brisbane, Queensland, Australia
| |
Collapse
|
24
|
Lambie D. Motivational interviewing to promote exercise behaviour change: a meta-ethnography using perspectives of patients and clinicians. Physiotherapy 2016. [DOI: 10.1016/j.physio.2016.10.369] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
25
|
Tan J, Lambie D, Sinnya S, Sahebian A, Soyer H, Prow T, Ardigò M. Histopathology and reflectance confocal microscopy features of photodamaged skin and actinic keratosis. J Eur Acad Dermatol Venereol 2016; 30:1901-1911. [DOI: 10.1111/jdv.13699] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2015] [Accepted: 03/04/2016] [Indexed: 12/18/2022]
Affiliation(s)
- J.M. Tan
- Dermatology Research Centre; The University of Queensland; School of Medicine; Translational Research Institute; Brisbane Queensland Australia
| | - D. Lambie
- Dermatology Research Centre; The University of Queensland; School of Medicine; Translational Research Institute; Brisbane Queensland Australia
- IQ Pathology; Brisbane Queensland Australia
| | - S. Sinnya
- Dermatology Research Centre; The University of Queensland; School of Medicine; Translational Research Institute; Brisbane Queensland Australia
| | - A. Sahebian
- Dermatology Research Centre; The University of Queensland; School of Medicine; Translational Research Institute; Brisbane Queensland Australia
| | - H.P. Soyer
- Dermatology Research Centre; The University of Queensland; School of Medicine; Translational Research Institute; Brisbane Queensland Australia
| | - T.W. Prow
- Dermatology Research Centre; The University of Queensland; School of Medicine; Translational Research Institute; Brisbane Queensland Australia
| | - M. Ardigò
- San Gallicano Dermatological Institute; Rome Italy
| |
Collapse
|
26
|
Fox C, Lambie D, Wilmott JS, Pinder A, Pavey S, Lê Cao KA, Akalin T, Karaarslan IK, Ozdemir F, Scolyer RA, Yamada M, Soyer HP, Schaider H, Gabrielli B. Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation. Pigment Cell Melanoma Res 2016; 29:444-52. [PMID: 27166757 DOI: 10.1111/pcmr.12489] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2015] [Accepted: 05/04/2016] [Indexed: 11/27/2022]
Abstract
Here we have carried out a multiparameter analysis using a panel of 28 immunohistochemical markers to identify markers of transformation from benign and dysplastic naevus to primary melanoma in three separate cohorts totalling 279 lesions. We have identified a set of eight markers that distinguish naevi from melanoma. None of markers or parameters assessed differentiated benign from dysplastic naevi. Indeed, the naevi clustered tightly in terms of their immunostaining patterns whereas primary melanomas showed more diverse staining patterns. A small subset of histopathologically benign lesions had elevated levels of multiple markers associated with melanoma, suggesting that these represent naevi with an increased potential for transformation to melanoma.
Collapse
Affiliation(s)
- Carly Fox
- The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Qld, Australia
| | | | | | - Alex Pinder
- The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Qld, Australia
| | - Sandra Pavey
- The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Qld, Australia
| | - Kim-Anh Lê Cao
- The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Qld, Australia
| | - Taner Akalin
- Department of Pathology, Ege University, Izmir, Turkey
| | | | - Fezal Ozdemir
- Department of Dermatology, Ege University, Izmir, Turkey
| | | | - Miko Yamada
- Dermatology Research Centre, Translational Research Institute, The University of Queensland School of Medicine, Brisbane, Qld, Australia
| | - H Peter Soyer
- Dermatology Research Centre, Translational Research Institute, The University of Queensland School of Medicine, Brisbane, Qld, Australia
| | - Helmut Schaider
- Dermatology Research Centre, Translational Research Institute, The University of Queensland School of Medicine, Brisbane, Qld, Australia
| | - Brian Gabrielli
- The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Qld, Australia
| |
Collapse
|
27
|
Rowe CJ, Tang F, Hughes MCB, Rodero MP, Malt M, Lambie D, Barbour A, Hayward NK, Smithers BM, Green AC, Khosrotehrani K. Molecular markers to complement sentinel node status in predicting survival in patients with high-risk locally invasive melanoma. Int J Cancer 2016; 139:664-72. [PMID: 26990817 DOI: 10.1002/ijc.30085] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2015] [Revised: 02/08/2016] [Accepted: 02/29/2016] [Indexed: 11/11/2022]
Abstract
Sentinel lymph node status is a major prognostic marker in locally invasive cutaneous melanoma. However, this procedure is not always feasible, requires advanced logistics and carries rare but significant morbidity. Previous studies have linked markers of tumour biology to patient survival. In this study, we aimed to combine the predictive value of established biomarkers in addition to clinical parameters as indicators of survival in addition to or instead of sentinel node biopsy in a cohort of high-risk melanoma patients. Patients with locally invasive melanomas undergoing sentinel lymph node biopsy were ascertained and prospectively followed. Information on mortality was validated through the National Death Index. Immunohistochemistry was used to analyse proteins previously reported to be associated with melanoma survival, namely Ki67, p16 and CD163. Evaluation and multivariate analyses according to REMARK criteria were used to generate models to predict disease-free and melanoma-specific survival. A total of 189 patients with available archival material of their primary tumour were analysed. Our study sample was representative of the entire cohort (N = 559). Average Breslow thickness was 2.5 mm. Thirty-two (17%) patients in the study sample died from melanoma during the follow-up period. A prognostic score was developed and was strongly predictive of survival, independent of sentinel node status. The score allowed classification of risk of melanoma death in sentinel node-negative patients. Combining clinicopathological factors and established biomarkers allows prediction of outcome in locally invasive melanoma and might be implemented in addition to or in cases when sentinel node biopsy cannot be performed.
Collapse
Affiliation(s)
- Casey J Rowe
- The University of Queensland Diamantina Institute, Translational Research Institute, Woolloongabba, QLD, Australia.,The University of Queensland Centre for Clinical Research, Brisbane, QLD, Australia
| | - Fiona Tang
- Department of Anatomical Pathology, Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
| | - Maria Celia B Hughes
- Cancer and Population Studies, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - Mathieu P Rodero
- The University of Queensland Centre for Clinical Research, Brisbane, QLD, Australia
| | - Maryrose Malt
- Cancer and Population Studies, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - Duncan Lambie
- The University of Queensland Diamantina Institute, Translational Research Institute, Woolloongabba, QLD, Australia.,IQ Pathology, West End, Brisbane, QLD, Australia
| | - Andrew Barbour
- Queensland Melanoma Project, Princess Alexandra Hospital, The University of Queensland, Brisbane, QLD, Australia
| | - Nicholas K Hayward
- Oncogenomics, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | - B Mark Smithers
- Queensland Melanoma Project, Princess Alexandra Hospital, The University of Queensland, Brisbane, QLD, Australia
| | - Adele C Green
- Cancer and Population Studies, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.,Cancer Research UK Manchester Institute and Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom
| | - Kiarash Khosrotehrani
- The University of Queensland Diamantina Institute, Translational Research Institute, Woolloongabba, QLD, Australia.,The University of Queensland Centre for Clinical Research, Brisbane, QLD, Australia
| |
Collapse
|
28
|
Fox C, Schaider H, Akalin T, Turkmen M, Sturm R, Lambie D, Karaarslan IK, Soyer HP, Ozdemir F, Gabrielli B. A distinct expression profile separates Turkish and Australian melanocytic naevi. Histopathology 2015; 69:151-4. [PMID: 26599517 DOI: 10.1111/his.12906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Carly Fox
- The University of Queensland Diamantina Institute, Brisbane, Queensland, Australia
| | - Helmut Schaider
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia
| | - Taner Akalin
- Department of Pathology, Ege University, Izmir, Turkey
| | - Meltem Turkmen
- Department of Dermatology, Ege University, Izmir, Turkey
| | - Rick Sturm
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia
| | | | | | - H Peter Soyer
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia
| | - Fezal Ozdemir
- Department of Dermatology, Ege University, Izmir, Turkey
| | - Brian Gabrielli
- The University of Queensland Diamantina Institute, Brisbane, Queensland, Australia
| |
Collapse
|
29
|
Tan JM, Lin LL, Lambie D, Flewell-Smith R, Jagirdar K, Schaider H, Sturm RA, Prow TW, Soyer HP. BRAF wild-type melanoma in situ arising in a BRAF V600E mutant dysplastic nevus. JAMA Dermatol 2015; 151:417-21. [PMID: 25607474 DOI: 10.1001/jamadermatol.2014.3775] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
IMPORTANCE The BRAF V600E mutation accounts for the majority of BRAF mutations found in cutaneous melanoma and is also commonly found in nevi. We used dermoscopy-targeted sampling and a microbiopsy device coupled with DNA sequence analysis to highlight BRAF V600E heterogeneity within a multicomponent melanocytic proliferation. This sampling technique demonstrates the prospect of in vivo application in a clinical setting. OBSERVATIONS A man in his 50s with Fitzpatrick skin type II presented with an irregularly pigmented melanocytic lesion on his back that met melanoma-specific dermoscopic criteria, and diagnostic shave excision of the lesion was performed. Histopathologic analysis revealed a melanoma in situ arising in a dysplastic nevus. Dermoscopy-targeted microbiopsy specimens were taken across the lesion, and genotyping was carried out on extracted DNA samples for BRAF and NRAS mutations. The melanoma in situ showed only BRAF wild-type results, while the dysplastic nevus showed both BRAF wild-type and BRAF V600E mutations. Sequencing in all DNA samples revealed NRAS wild-type genotype. CONCLUSIONS AND RELEVANCE Dermoscopy-targeted sampling and genotyping of a melanoma in situ arising in a dysplastic nevus revealed a phenotype-genotype paradox that confounds the exclusive significance of BRAF and NRAS mutations in melanoma pathogenesis. Further studies are required to investigate the importance of other candidate genes linked to melanomagenesis.
Collapse
Affiliation(s)
- Jean-Marie Tan
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Australia
| | - Lynlee L Lin
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Australia
| | - Duncan Lambie
- School of Medicine, The University of Queensland, Brisbane, Australia3IQ Pathology, Brisbane, Queensland, Australia
| | - Ross Flewell-Smith
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Australia
| | - Kasturee Jagirdar
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Australia
| | - Helmut Schaider
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Australia
| | - Richard A Sturm
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Australia
| | - Tarl W Prow
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Australia
| | - H Peter Soyer
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Australia
| |
Collapse
|
30
|
Chai RC, Lambie D, Verma M, Punyadeera C. Current trends in the etiology and diagnosis of HPV-related head and neck cancers. Cancer Med 2015; 4:596-607. [PMID: 25644715 PMCID: PMC4402074 DOI: 10.1002/cam4.424] [Citation(s) in RCA: 83] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Revised: 11/18/2014] [Accepted: 12/18/2014] [Indexed: 12/15/2022] Open
Abstract
Human papilloma virus (HPV) infection is a major risk factor for a distinct subset of head and neck squamous cell carcinoma (HNSCC). The current review summarizes the epidemiology of HNSCC and the disease burden, the infectious cycle of HPV, the roles of viral oncoproteins, E6 and E7, and the downstream cellular events that lead to malignant transformation. Current techniques for the clinical diagnosis of HPV-associated HNSCC will also be discussed, that is, the detection of HPV DNA, RNA, and the HPV surrogate marker, p16 in tumor tissues, as well as HPV-specific antibodies in serum. Such methods do not allow for the early detection of HPV-associated HNSCC and most cases are at an advanced stage upon diagnosis. Novel noninvasive approaches using oral fluid, a clinically relevant biological fluid, allow for the detection of HPV and cellular alterations in infected cells, which may aid in the early detection and HPV-typing of HNSCC tumors. Noninvasive diagnostic methods will enable early detection and intervention, leading to a significant reduction in mortality and morbidity associated with HNSCC.
Collapse
Affiliation(s)
- Ryan C Chai
- The University of Queensland Diamantina Institute, The University of Queensland, The Translational Research Institute, Woolloongabba, Queensland, 4102, Australia
| | | | | | | |
Collapse
|
31
|
McClenahan P, Lin LL, Tan JM, Flewell-Smith R, Schaider H, Jagirdar K, Atkinson V, Lambie D, Prow TW, Sturm RA, Soyer HP. BRAFV600E mutation status of involuting and stable nevi in dabrafenib therapy with or without trametinib. JAMA Dermatol 2015; 150:1079-82. [PMID: 24695877 DOI: 10.1001/jamadermatol.2014.436] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
IMPORTANCE Recent advances in targeting BRAFV600E mutations, which occur in roughly 50% of melanomas and 70% of benign nevi, have improved response rates and survival in patients with melanoma. With increased survival, the importance of other comorbidities increases and requires consideration in long-term management. This case report discusses dynamic dermoscopic nevus changes that occur during dabrafenib therapy and offers some conclusions regarding BRAF mutations and the changes. OBSERVATIONS A man in his 30s had been monitored with whole-body dermoscopy at roughly 7-month intervals as part of a nevus surveillance study. Fourteen months after his initial visit, metastases were found, and the patient entered a clinical trial of dabrafenib with or without trametinib therapy. Continued dermoscopic monitoring for the next 12 months revealed that approximately 50% of the existing acquired melanocytic nevi involuted, while the remaining nevi did not change. Biopsy findings from 1 unchanged and 1 involuted nevus showed BRAF wild type in the unchanged nevus, BRAFV600E mutation in the involuting nevus, and no malignant histopathologic characteristics in either one. CONCLUSIONS AND RELEVANCE Our observations indicate that a previously suggested hypothesis regarding involuting nevi in BRAF inhibitor therapy is correct: Nevi that involute while a patient is undergoing BRAF V600E inhibitor therapy possess the BRAF V600E mutation, while others that grow or remain unchanged are wild type. However larger-scale trials are required to gather conclusive data and create a more complete clinical picture.
Collapse
Affiliation(s)
- Phil McClenahan
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia
| | - Lynlee L Lin
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia
| | - Jean-Marie Tan
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia
| | - Ross Flewell-Smith
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia
| | - Helmut Schaider
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia
| | - Kasturee Jagirdar
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia2The University of Queensland, Institute for Molecular Biosciences, Brisbane, Queensland, Australia
| | - Victoria Atkinson
- Medical Oncology, Princess Alexandra Hospital, Wooloongabba, Queensland, Australia
| | - Duncan Lambie
- The University of Queensland, Translational Research Institute, Brisbane, Queensland, Australia5IQ Pathology, Brisbane, Queensland, Australia
| | - Tarl W Prow
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia
| | - Richard A Sturm
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia2The University of Queensland, Institute for Molecular Biosciences, Brisbane, Queensland, Australia
| | - H Peter Soyer
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia
| |
Collapse
|
32
|
Barbour AP, Tang YH, Armour N, Dutton-Regester K, Krause L, Loffler KA, Lambie D, Burmeister B, Thomas J, Smithers BM, Hayward NK. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy. Eur J Cancer 2014; 50:2668-76. [PMID: 25070294 DOI: 10.1016/j.ejca.2014.06.009] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2014] [Revised: 06/13/2014] [Accepted: 06/13/2014] [Indexed: 02/09/2023]
Abstract
BACKGROUND 5-year survival for melanoma metastasis to regional lymph nodes (American Joint Committee on Cancer stage III) is <50%. Knowledge of outcomes following therapeutic lymphadenectomy for stage III melanoma related to BRAF status may guide adjuvant use of BRAF/MEK inhibitors along with established and future therapies. AIMS To determine patterns of melanoma recurrence and survival following therapeutic lymph node dissection (TLND) associated with oncogenic mutations. METHODS DNA was obtained from patients who underwent TLND and had ⩾2 positive nodes, largest node >3cm or extracapsular invasion. Mutations were detected using an extended Sequenom MelaCARTA panel. RESULTS Mutations were most commonly detected in BRAF (57/124 [46%] patients) and NRAS (26/124 [21%] patients). Patients with BRAF mutations had higher 3-year recurrence rate (77%) versus 54% for BRAF wild-type patients (hazard ratio (HR) 1.8, p=0.008). The only prognostically significant mutations occurred in BRAF: median recurrence-free (RFS) and disease-specific survival (DSS) for BRAF mutation patients was 7 months and 16 months, versus 19 months and not reached for BRAF wild-type patients, respectively. Multivariate analysis identified BRAF mutant status and number of positive lymph nodes as the only independent prognostic factors for RFS and DSS. CONCLUSIONS Patients with BRAF mutations experienced rapid progression of metastatic disease with locoregional recurrence rarely seen in isolation, supporting incorporation of BRAF status into melanoma staging and use of BRAF/MEK inhibitors post-TLND.
Collapse
Affiliation(s)
- Andrew P Barbour
- Surgical Oncology Group, School of Medicine, The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia; Queensland Melanoma Project, Discipline of Surgery, The University of Queensland, Princess Alexandra Hospital, Woolloongabba, QLD, Australia.
| | - Yue Hang Tang
- Surgical Oncology Group, School of Medicine, The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia
| | - Nicola Armour
- Surgical Oncology Group, School of Medicine, The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia
| | - Ken Dutton-Regester
- QIMR Berghofer Medical Research Institute, Oncogenomics Laboratory, Brisbane, QLD, Australia
| | - Lutz Krause
- QIMR Berghofer Medical Research Institute, Oncogenomics Laboratory, Brisbane, QLD, Australia
| | - Kelly A Loffler
- Surgical Oncology Group, School of Medicine, The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia
| | - Duncan Lambie
- Department of Pathology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia
| | - Bryan Burmeister
- Queensland Melanoma Project, Discipline of Surgery, The University of Queensland, Princess Alexandra Hospital, Woolloongabba, QLD, Australia
| | - Janine Thomas
- Queensland Melanoma Project, Discipline of Surgery, The University of Queensland, Princess Alexandra Hospital, Woolloongabba, QLD, Australia
| | - B Mark Smithers
- Queensland Melanoma Project, Discipline of Surgery, The University of Queensland, Princess Alexandra Hospital, Woolloongabba, QLD, Australia
| | - Nicholas K Hayward
- QIMR Berghofer Medical Research Institute, Oncogenomics Laboratory, Brisbane, QLD, Australia
| |
Collapse
|
33
|
Shiohira S, Yoshida T, Sugiura H, Nishida M, Nitta K, Tsuchiya K, Grampp S, Goppelt-Strube M, Eckardt KU, Schodel J, Kang SW, Kim Y, Seo SK, Kim T, Ong S, Yang WS, Han NJ, Lee JM, Baek CH, Park SK, Kemter E, Aigner B, Wanke R, Troyano Suarez N, Olmos Centenero G, Mora I, Griera M, Cano JL, Martin P, Zamora J, Ruiz-Torres MP, Falke LL, Leask A, Lyons K, Nguyen TQ, Goldschmeding R, Park SK, Kim D, Lee AS, Jung YJ, Yang KH, Lee S, Kim W, Kim W, Kang KP, Garcia-Jerez A, Luengo-Rodriguez A, Ramirez-Chamond R, Carracedo J, Medrano-Andres D, Rodriguez-Puyol D, Calleros L, Kim HW, Park SK, Yang WS, Lee SK, Chang JW, Seo JW, Lee CT, Chou CA, Lee YT, Ng HY, Sanchez-Nino MD, Fernandez-Fernandez B, Perez-Gomez MV, Poveda J, Sanz AB, Cannata-Ortiz P, Egido J, Selgas R, Ortiz A, Ma SK, Kim IJ, Kim CS, Bae EH, Kim SW, Kokeny G, Boo'Si M, Fazekas K, Rosivall L, Mozes MM, Mijuskovic M, Ulrich C, Berger H, Trojanowicz B, Kohler F, Wolf A, Seibert E, Fiedler R, Markau S, Glomb M, Girndt M, Lajdova I, Spustova V, Oksa A, Chorvat D, Marcek Chorvatova A, Choi SO, Kim JS, Han BG, Yang JW, Liu S, Lv J, Chang R, Su F, Liang W, Zawada AM, Rogacev KS, Hundsdorfer J, Sester U, Fliser D, Heine GH, Chen JS, Cheng CW, Chang LC, Wu CZ, Novaes AS, Borges FT, Boim MA, Tramonti G, Romiti N, Chieli E, Hamahata S, Nagasawa Y, Kawabe M, Kida A, Yahiro M, Nanami M, Hasuike Y, Kuragano T, Nakasho K, Ohyama H, Nakanishi T, Tanaka S, Yano S, Sugimoto T, Bae E, Stevens KK, Hillyard DZ, Delles C, Jardine AG, Burke M, Morais C, Soyer P, Sinnya S, Winterford C, Oliver K, Lambie D, Staatz C, Carroll R, Campbell S, Isbel N, Felaco P, Pesce M, Patruno A, Sirolli V, Speranza L, Amoroso L, Franceschelli S, Bonomini M, Thilo F, Zakrzewicz A, Tepel M, Thilo F, Zakrzewicz A, Tepel M, Liu S, Li Y, Liang W, Su F, Wang B. CELL SIGNALLING AND APOPTOSIS. Nephrol Dial Transplant 2014. [DOI: 10.1093/ndt/gfu161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Al-Tuwirqi A, Lambie D, Seow WK. Regional odontodysplasia: literature review and report of an unusual case located in the mandible. Pediatr Dent 2014; 36:62-67. [PMID: 24717712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
The purpose of this report was to describe the clinical, radiological, and histopathological features of a case of regional odonto- dysplasia (RA) in a seven-year-old boy who was followed for approximately two years. The case is unusual in that the dysplasia occurred in the mandible, and there was a normal-appearing tooth within the lesion, suggesting that there may be local factors that determine susceptibility of individual teeth in RA. The diagnosis of RA was based on the typical features of "ghost" teeth and evidence of disrupted calcification characterized by psammomatous bodies, hypomineralization of enamel, and the presence of interglobular dentin. Sequential orthopantomograms provide evidence of delayed dental development.
Collapse
Affiliation(s)
- Amani Al-Tuwirqi
- Assistant professor, School of Dentistry, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Duncan Lambie
- Consultant pathologist, Pathology Queensland, Princess Alexandra Hospital, Queensland Health, Queensland, Australia
| | - W Kim Seow
- Professor and director, Center for Pediatric Dentistry, School of Dentistry, University of Queensland, Brisbane, Queensland, Australia.
| |
Collapse
|
35
|
Panizza B, Warren TA, Solares CA, Boyle GM, Lambie D, Brown I. Histopathological features of clinical perineural invasion of cutaneous squamous cell carcinoma of the head and neck and the potential implications for treatment. Head Neck 2013; 36:1611-8. [PMID: 24115192 DOI: 10.1002/hed.23509] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2012] [Revised: 08/15/2013] [Accepted: 09/10/2013] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Nonmelanoma skin cancer (NMSC) with perineural invasion (PNI) is most commonly seen in cutaneous squamous cell carcinoma of the head and neck (SCCHN). The cranial nerves are a conduit for skin cancer to reach the brainstem. METHODS The histopathological features of 51 tissue specimens from 49 patients with cutaneous SCCHN and clinical PNI were assessed with consecutive transverse and longitudinal sections. RESULTS No skip lesions were identified. Tumor spread was contiguous in all specimens. No tumor spread into the perineural space from surrounding or adjacent tumor was seen. Proximal large cranial nerves showed epineural involvement in 3.9% in areas with large tumor bulk, extensive PNI, and intraneural invasion. CONCLUSION Perineural tumor spread in cutaneous SCCHN was contiguous and no skip lesions were evident in nerve specimens assessed in this series. Spread beyond cranial nerve perineurium was uncommon, reflecting its multilayer barrier function at this level. These findings may have treatment implications.
Collapse
Affiliation(s)
- Benedict Panizza
- Department of Otolaryngology, Head and Neck Surgery and Queensland Skull Base Unit, Princess Alexandra Hospital, Brisbane, Queensland, Australia; School of Medicine, University of Queensland, Brisbane, Queensland, Australia
| | | | | | | | | | | |
Collapse
|
36
|
Banan P, Lin LL, Lambie D, Prow T, Soyer HP. Effects of ex vivo skin microbiopsy on histopathologic diagnosis in melanocytic skin lesions. JAMA Dermatol 2013; 149:1107-9. [PMID: 23864191 DOI: 10.1001/jamadermatol.2013.5020] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Affiliation(s)
- Parastoo Banan
- Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Queensland, Australia
| | | | | | | | | |
Collapse
|
37
|
Chikani V, Lambie D, Russell A. Pituitary metastases from papillary carcinoma of thyroid: a case report and literature review. Endocrinol Diabetes Metab Case Rep 2013; 2013:130024. [PMID: 24616765 PMCID: PMC3922192 DOI: 10.1530/edm-13-0024] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2013] [Accepted: 07/22/2013] [Indexed: 11/12/2022] Open
Abstract
Metastases to the pituitary gland are an uncommon complication of thyroid cancer. They resemble pituitary neoplasms posing a diagnostic challenge. We present a case of an aggressive non-radioiodine avid papillary thyroid cancer with recurrent pituitary metastases and a review of the literature. A 70-year-old woman with a history of papillary thyroid cancer and bony metastases presented with symptoms of hypoadrenalism and peripheral vision loss. Magnetic resonance imaging showed a large pituitary mass impinging on the optic chiasm. She underwent transsphenoidal resection followed by 131I ablation. Post-therapy scintigraphy showed no iodine uptake in the sellar region or bony metastases. Histology of the pituitary mass confirmed metastatic papillary thyroid cancer. Fifteen months later, she had a recurrence of pituitary metastases affecting her vision. This was resected and followed with external beam radiotherapy. Over 2 years, the pituitary metastases increased in size and required two further operations. Radioactive iodine was not considered due to poor response in the past. Progressively, she developed a left-sided III and IV cranial nerve palsy and permanent bitemporal hemianopia. There was a rapid decline in the patient's health with further imaging revealing new lung and bony metastases, and she eventually died 8 months later. To our knowledge, this is the first case of pituitary metastases from a radioiodine-resistant papillary thyroid cancer. Radioiodine-resistant metastatic thyroid cancer may exhibit rapid aggressive growth and remain poorly responsive to the currently available treatment.
Collapse
Affiliation(s)
- Viral Chikani
- Department of Diabetes and Endocrinology The Princess Alexandra Hospital 199 Ipswich Road, Woolloongabba, Queensland, 4102 Australia
| | - Duncan Lambie
- Department of Anatomical Pathology The Princess Alexandra Hospital 199 Ipswich Road, Woolloongabba, Queensland, 4102 Australia
| | - Anthony Russell
- Department of Diabetes and Endocrinology The Princess Alexandra Hospital 199 Ipswich Road, Woolloongabba, Queensland, 4102 Australia
| |
Collapse
|
38
|
Panizza B, Warren TA, Lambie D, Brown I. The fallacy of skip lesions as an example of misinterpretations being propagated in the scientific literature. Oral Oncol 2012; 48:e33-e34. [DOI: 10.1016/j.oraloncology.2012.05.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2012] [Accepted: 05/03/2012] [Indexed: 11/15/2022]
|
39
|
Bennett NC, Hooper JD, Lambie D, Lee CS, Yang T, Vesey DA, Samaratunga H, Johnson DW, Gobe GC. Evidence for steroidogenic potential in human prostate cell lines and tissues. Am J Pathol 2012; 181:1078-87. [PMID: 22796438 DOI: 10.1016/j.ajpath.2012.06.009] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/03/2011] [Revised: 04/19/2012] [Accepted: 06/07/2012] [Indexed: 11/25/2022]
Abstract
Malignant prostate cancer (PCa) is usually treated with androgen deprivation therapies (ADTs). Recurrent PCa is resistant to ADT. This research investigated whether PCa can potentially produce androgens de novo, making them androgen self-sufficient. Steroidogenic enzymes required for androgen synthesis from cholesterol (CYP11A1, CYP17A1, HSD3β, HSD17β3) were investigated in human primary PCa (n = 90), lymph node metastases (LNMs; n = 8), and benign prostatic hyperplasia (BPH; n = 6) with the use of IHC. Six prostate cell lines were investigated for mRNA and protein for steroidogenic enzymes and for endogenous synthesis of testosterone and 5α-dihydrotestosterone. All enzymes were identified in PCa, LNMs, BPH, and cell lines. CYP11A1 (rate-limiting enzyme) was expressed in cancerous and noncancerous prostate glands. CYP11A1, CYP17A1, HSD3β, and HSD17β3 were identified, respectively, in 78%, 52%, 16%, and 82% of human BPH and PCa samples. Approximately 10% of primary PCa, LNMs, and BPH expressed all four enzymes simultaneously. CYP11A1 expression was stable, CYP17A1 increased, and HSD3β and HSD17β3 decreased with disease progression. CYP17A1 expression was significantly correlated with CYP11A1 (P = 0.0009), HSD3β (P = 0.0297), and HSD17β3 (P = 0.0090) in vivo, suggesting CYP17A1 has a key role in prostatic steroidogenesis similar to testis and adrenal roles. In vitro, all cell lines expressed mRNA for all enzymes. Protein was not always detectable; however, all cell lines synthesized androgen from cholesterol. The results indicate that monitoring steroidogenic metabolites in patients with PCa may provide useful information for therapy intervention.
Collapse
Affiliation(s)
- Nigel C Bennett
- School of Medicine, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Wurm EMT, Lin LL, Ferguson B, Lambie D, Prow TW, Walker GJ, Soyer HP. A blueprint for staging of murine melanocytic lesions based on the Cdk4 ( R24C/R24C ) ::Tyr- NRAS ( Q ) ( 61K ) model. Exp Dermatol 2012; 21:676-81. [PMID: 22742762 DOI: 10.1111/j.1600-0625.2012.01543.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/24/2012] [Indexed: 12/22/2022]
Abstract
It has been shown that gene mutations which drive the development of malignant melanoma (MM) in humans also lead to emergence of MM when engineered mice. However, little attention has been paid to the clinical and histopathological features of melanocytic lesions and their natural history in a given mouse model. This knowledge is crucial to enable us to understand how engineered mutations influence the initiation and evolution of melanocytic lesions, and/or for the use of mice as a preclinical model to test specific treatments. We recently reported the development of melanocytic proliferations along the spectrum of naevi to MM in a Cdk4 ( R24C/R24C ) ::Tyr- NRAS ( Q ) ( 61K ) mouse model. In this study, we followed the development of lesions over time using digital photography and dermoscopy with the aim to correlate the clinical and histopathological features of lesions developing in this model. We identified two types of lesions. The first are slow-growing dermal MMs that emanate from dermal naevi. The second did not emanate from naevi, grew rapidly, and appeared to be solely confined to the subcutaneous fat. We present a simple staging system for the MMs that progress from naevi, based on depth of extension into the dermis and subcutis. This represents a blueprint for documentation and follow-up of MMs in the live animal, which is critical for the proper use of murine melanoma models.
Collapse
Affiliation(s)
- Elisabeth M T Wurm
- Dermatology Research Centre, The University of Queensland, School of Medicine, Princess Alexandra Hospital, Brisbane, QLD, Australia
| | | | | | | | | | | | | |
Collapse
|
41
|
Wurm EM, Curchin CE, Lambie D, Longo C, Pellacani G, Soyer HP. Confocal features of equivocal facial lesions on severely sun-damaged skin: Four case studies with dermatoscopic, confocal, and histopathologic correlation. J Am Acad Dermatol 2012; 66:463-73. [DOI: 10.1016/j.jaad.2011.02.040] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2010] [Revised: 01/07/2011] [Accepted: 02/15/2011] [Indexed: 01/23/2023]
|
42
|
Webber SA, Wurm EMT, Douglas NC, Lambie D, Longo C, Pellacani G, Soyer HP. Effectiveness and limitations of reflectance confocal microscopy in detecting persistence of basal cell carcinomas: a preliminary study. Australas J Dermatol 2011; 52:179-85. [PMID: 21834812 DOI: 10.1111/j.1440-0960.2011.00769.x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND/OBJECTIVES Reflectance confocal microscopy (RCM) can accurately and non-invasively diagnose basal cell carcinoma (BCC). The use of RCM in assessing responses to saucerization or curettage and cautery of BCC has not been established. The aim of the present study was to expound the usefulness of RCM in assessing treatment responses of BCC to saucerization or curettage and cautery 8-12 weeks after treatment. METHODS Eight sequential patients, with 11 superficial BCCs, were recruited. Lesions were evaluated clinically and dermoscopically. Three operators performed RCM imaging for each BCC at baseline and 8-12 weeks after treatment. Diagnostic criteria for RCM diagnosis included streaming of basal cells and the presence of cord-like structures and horizontal vessels. Results were compared against histopathology. Difficulties in establishing tumour clearance were identified and the effectiveness of RCM in assessing the response to treatment was explored. RESULTS At baseline, all lesions were consistent with superficial BCC. At 8-12 weeks after treatment, RCM correctly diagnosed 10 of 11 lesions as tumour free. Furthermore, RCM was reliable across operators of variable experience and the findings were confirmed histopathologically. Limitations were identified, but appeared to be related to operator experience. CONCLUSION The diagnosis of BCC was straightforward and reliable in the present study. Thus, RCM appears useful in assessing the early treatment response of superficial BCC treated with saucerization or curettage and cautery despite operator-dependent limitations.
Collapse
Affiliation(s)
- Scott A Webber
- Department of Dermatology, The University of Queensland, School of Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
| | | | | | | | | | | | | |
Collapse
|
43
|
Bettington A, Lambie D. Intraductal papillary mucinous neoplasms of the pancreas – a review of four cases with pre-operative cytological examination. Pathology 2010. [DOI: 10.1097/01268031-201042001-00140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
44
|
Tang YM, Stuckey S, Lambie D, Strutton GM. Macroscopic vascular invasion in synovial sarcoma evident on MRI. Skeletal Radiol 2006; 35:783-6. [PMID: 16132983 DOI: 10.1007/s00256-005-0934-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2005] [Revised: 03/23/2005] [Accepted: 03/23/2005] [Indexed: 02/02/2023]
Abstract
We present a case of recurrent synovial sarcoma in the soft tissues of the calf, where MR imaging not only confirmed the diagnosis of tumour recurrence, but also demonstrated direct venous invasion and tumour thrombus within the popliteal vein and its tributaries. Venous invasion has particular relevance to synovial sarcoma prognostication and should be actively sought on MR imaging. To our knowledge this is the first reported case in the English literature of histologically proven macroscopic popliteal vein invasion from a synovial sarcoma demonstrated on MR imaging.
Collapse
Affiliation(s)
- Y M Tang
- Department of Radiology, Princess Alexandra Hospital, Ipswich Road, Qld 4102, Woolloongabba, Brisbane, Australia.
| | | | | | | |
Collapse
|
45
|
|
46
|
|
47
|
|